Home › Targets › RET
Radioligand therapy target profile

RET: IHC Expression in Cancer and Radioligand Target Profile

ret proto-oncogene · Ensembl ENSG00000165731 · Data updated 2026-11-16

RET, ret proto-oncogene, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, RET staining is highest in melanoma (100% of samples positive), prostate cancer (92% of samples positive) and liver cancer (80% of samples positive). Clinical status: FDA-approved drug (any modality), with 15 active clinical trials.

Is RET the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze RET free
LocalizationCell-Surface
Top cancer (IHC)Melanoma
InternalizationNot assessed
Clinical stageFDA-approved drug (any modality)
Active trials15
Cancer association (Open Targets)0.94

Is RET a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

RET IHC staining by cancer type

Protein expression of RET across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Melanoma0.92High100%
Prostate Cancer0.58High92%
Liver Cancer0.50Medium80%
Neuroendocrine Tumors0.42Medium75%
Glioma0.36Medium50%
Pancreatic Cancer0.33Medium67%
Cervical Cancer0.28Medium58%
Head and Neck Cancer0.25Medium50%
Lung Cancer0.25Medium50%
Thyroid Cancer0.25Medium25%
Gastric Cancer0.22Medium42%
Bladder Cancer0.19Low58%
Breast Cancer0.19Low42%
Ovarian Cancer0.18Low46%
Endometrial Cancer0.15Low36%
Lymphoma0.14Low42%
Testicular Cancer0.14Low33%
Skin Cancer0.12Low36%
Kidney Cancer0.09Low18%
Colorectal Cancer0.06Low18%

Is RET internalized?

Nuclens has not yet extracted internalization evidence for RET. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.

RET clinical trials

FDA-approved drug (any modality). 15 active trials reference RET (ClinicalTrials.gov, accessed 2026-11-16).

NCT07931261 · NCT07019766 · NCT03775265 · NCT01711554 · NCT07153263 · NCT04374305 · NCT07929441 · NCT07934927 · NCT07709000 · NCT07927998 · NCT06149481 · NCT04164082

RET normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See RET in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

RET gene essentiality (DepMap)

CRISPR knockout effect across 1256 cancer cell lines: -0.12 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related melanoma radioligand targets

HER3 (ERBB3) · c-MET (MET) · SSTR2 · STEAP2 · ITGAV · B7-H3 (CD276) · TMEFF2 · FAP

See all radioligand therapy targets in melanoma.

See how RET ranks against 15,000 targets for your indication.

Analyze RET free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is RET the right target for your program? · 5 free analyses, no card Analyze RET free